Uncategorized

Cagrilintide: the amylin half of CagriSema, and its own trial record

November 20, 2026  ·  6 min read  ·  How we write

The short version: Cagrilintide is Novo Nordisk’s long-acting version of amylin, a pancreatic hormone that signals fullness. It is the amylin half of CagriSema, but it has also been tested alone: in a 2021 phase 2 trial that included South African sites, and as its own arm in the REDEFINE 1 phase 3 trial, where it produced about half as much weight loss as the combination. Its own phase 3 programme, RENEW, started in November 2025 and has not reported. It is not approved anywhere.

View Cagrilintide & get a quote →

Amylin, the other fullness hormone

Talk about appetite hormones usually means GLP-1, the target of semaglutide. Amylin is a separate signal. It comes from the pancreas and, in the words of the phase 2 trial report, induces satiety.

The natural hormone is a difficult starting point for a drug. Amylin has a strong tendency to clump together into amyloid fibrils, long tangled strands of protein, so making a stable version takes careful design. One amylin analogue already exists as a medicine: pramlintide, used in diabetes alongside insulin. But it is short-acting.

Novo Nordisk’s chemists set out to fix both problems. In a 2021 paper in the Journal of Medicinal Chemistry they described how they arrived at cagrilintide: a stable amylin analogue with a fatty chain attached (the word they use is lipidated), designed to last far longer in the body than the natural hormone.

A separate route through the brain

A 2026 study in Nature Metabolism, by university researchers working with Novo Nordisk scientists, mapped more than 530,000 cells in the brainstem of rats, mice and macaques. In rats given cagrilintide over time, one group of neurons in a region called the nucleus of the solitary tract switched on a gene called Prlh. The same kind of neuron exists in rodents, macaques and humans.

When the team knocked that gene down in rats, cagrilintide’s effects disappeared, while semaglutide’s carried on. It’s animal work, but it shows the two drugs using different wiring, which is the case for pairing them.

The trial record

Cagrilintide has been tested on its own in a phase 2 trial and as a comparison arm in two phase 3 trials, and it now has a phase 3 programme of its own.

Trial Who and how long Cagrilintide alone Comparison
Phase 2 (Lancet, 2021) 706 adults on cagrilintide, no diabetes, 26 weeks, 57 sites in ten countries including South Africa 10.8% lower weight at the highest dose tested Placebo 3.0%; liraglutide 9.0%
REDEFINE 1 (phase 3, results 2025) 3,417 adults without diabetes, 302 of them on cagrilintide alone, 68 weeks Weight down 11.5% counting everyone; 11.8% if everyone had stayed on treatment Placebo 3.0% and 2.3%; CagriSema 20.4% and 22.7% on the same two measures
REIMAGINE 2 (phase 3, Lancet Diabetes & Endocrinology, 2026) 2,713 adults with type 2 diabetes, 152 on cagrilintide alone, 68 weeks A comparison arm; the trial’s question was blood sugar CagriSema lowered HbA1c more than semaglutide
RENEW 1 and RENEW 2 (phase 3) Started 5 November 2025; cagrilintide versus placebo for 64 weeks, one trial in people with overweight or obesity and one in people who also have type 2 diabetes No results yet Main data expected around May 2027, per the trial registry

See our lab reports before you order →

Reading those numbers properly

Two ways of counting run through these trials, and they’re easy to mix up. The REDEFINE 1 paper in the New England Journal of Medicine led with the stricter measure, which counts everyone regardless of whether they kept taking the drug. On that basis CagriSema came in at 20.4%, placebo at 3.0%. The cagrilintide-only figures came later, in a sub-analysis presented at the EASD diabetes meeting in September 2025. Its headline used the other measure, which estimates what happens if everyone stays on treatment: 11.8% for cagrilintide and 2.3% for placebo. Counting everyone, the figures were 11.5% and 3.0%.

Compare like with like: 11.5% against CagriSema’s 20.4% counting everyone, or 11.8% against the 22.7% Novo quoted when it filed CagriSema with the FDA. Either way, cagrilintide alone landed at a bit over half the combination.

Side effects

The pattern looks like the GLP-1 drugs. In the phase 2 trial, 41 to 63% of people across the cagrilintide groups reported stomach and gut side effects, against 32% on placebo, mostly nausea, constipation and diarrhoea. Injection-site reactions were also common. In REIMAGINE 2, 82.2% of the cagrilintide-only group reported some adverse event, against 70.5% on placebo.

One of Novo’s newer studies, a small feasibility trial that began recruiting in May 2026, is testing cagrilintide in people who stopped GLP-1 drugs because of gut side effects.

If you remember one thing: cagrilintide has real phase 2 and phase 3 data, but on its own it delivered about half the weight loss of CagriSema, and its own phase 3 programme hasn’t reported yet.

Where the evidence stops

  • No approval anywhere as a standalone drug. RENEW is the programme meant to answer that, and its main data is not expected before 2027.
  • The cagrilintide-only phase 3 numbers came through a conference presentation and company releases, not the main journal paper, which focused on the combination.
  • Every trial was sponsored by Novo Nordisk, with company employees among the authors.
  • The brain pathway work is in rats. It explains a mechanism. It doesn’t show the same thing in people.
  • CagriSema itself was still under review. Novo submitted it to the US FDA in December 2025, expecting a review during 2026.

A note on framing

Every figure in this article comes from Novo Nordisk’s pharmaceutical product, given to carefully selected adults in supervised trials, often alongside lifestyle advice. None of it describes research-grade material, and none of it transfers automatically to anyone outside those trials. We sell to researchers, and we’d rather you read the trial tables than a forum summary of them.

Where JP fits

JP Research supplies Cagrilintide as research-grade lyophilised powder in a 5mg vial, for laboratory research use only, with an independent Janoshik report on its product page. We also carry CagriSema and Semaglutide. For how amylin fits next to the GLP-1 family, see single, double, triple: how the GLP-1 research peptides differ, and our reconstitution and storage guide covers handling.

Browse the metabolic research range →

Sources

All JP Research products are supplied strictly for in-vitro research and laboratory use only. They are not intended for human or animal consumption, medical treatment, or diagnostic use. Nothing in this article constitutes medical advice.

Research access

Get restocks & our lab reports first

Restock alerts and the Certificates of Analysis we hold — straight to your phone. Research professionals only. No spam, leave anytime.

Chat to us